TECregen appoints Dr Klaas Zuideveld as CEO
Biotechnology company TECregen has appointed Dr Klaas Zuideveld as Chief Executive Officer.
Zuideveld will lead the company’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen immune resilience.
Zuideveld arrives with experience across large pharmaceutical companies and biotech, spanning translational strategy, clinical development, and global regulatory execution. He has also contributed to multiple IND clearances and global product approvals, leading teams through partnering, financing and value creation milestones across several therapeutic areas.
“TECregen’s approach to thymus regeneration addresses a central and underexplored mechanism underlying immune dysfunction,” Zuideveld said.
“With a strong scientific foundation, an expanding pipeline, and committed investor support, the company is well positioned to advance its programmes into clinical development and build a platform capable of delivering durable benefit for patients.”
The announcement follows TECregen’s recent CHF 10 million (€10.9 million) seed financing, as well as the appointment of Dr Bo Rode Hansen as Chairman of the Board.
“Klaas is a highly experienced leader with a proven ability to translate innovative science into rigorous clinical development programmes,” said Dr. Bo Rode Hansen, Chairman of TECregen.
“As TECregen advances its novel approach to restoring thymic function, his leadership will be instrumental in shaping the company’s development strategy and guiding its transition toward the clinic.”
